

ESMO PRECEPTORSHIP PROGRAMME

PROSTATE CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Lugano, Switzerland
18-19 December 2024

CO-CHAIRS Karim Fizazi, France
Silke Gillessen, Switzerland

SPEAKERS Giulia Baciarello, Italy
Elena Castro, Spain
Eva Compérat, Austria
Ken Herrmann, Germany
Jochen Walz, France
Thomas Zilli, Switzerland

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

Wednesday, 18 December 2024

09:00-09:10 10'	Opening and welcome	
10'	Welcome from ESMO - Objectives and scientific introduction	Karim Fizazi, FR Silke Gillessen, CH
09:10-10:50 100'	SESSION 1 Screening, diagnosis, staging and localised prostate cancer	Chairs: Eva Compérat, AT Jochen Walz, FR
15'	PSA screening and diagnosis	Jochen Walz, FR
10'	Staging	Jochen Walz, FR
15'	Pathological diagnosis for the clinician (including variants of PCa)	Eva Compérat, AT
15'	Treatment of localised prostate cancer according to risk category	Jochen Walz, FR
15'	Radiotherapeutic approaches for localised prostate cancer	Thomas Zilli, CH
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
10:50-11:20	Coffee break	

11:20-12:45 85'	SESSION 2 Biochemical relapse	Chairs: Giulia Baciarello, IT Thomas Zilli, CH
15'	Biochemical relapse: Definition and diagnostic algorithm	Giulia Baciarello, IT
20'	Rising PSA after radical local treatment: Prognosis, indications for salvage local treatments, salvage vs adjuvant treatments	Thomas Zilli, CH
20'	Use of early vs deferred systemic treatments in high-risk localized CaP and biochemical failures	Karim Fizazi, FR
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
12:45-13:45	Lunch	
13:45-15:25 100'	SESSION 3 Systemic treatment options and molecular characterisation	Chairs: Elena Castro, ES Jochen Walz, FR
20'	ADT and other hormonal treatments, mechanisms of action, main efficacy results and toxicities	Silke Gillessen, CH
20'	Chemotherapy (taxanes and platins) and Radium-223, mechanism of action, main efficacy results in Castration-Resistant Prostate Cancer (CRPC) and toxicities	Elena Castro, ES
15'	Bone health agents, mechanism of action, efficacy and toxicities	Giulia Baciarello, IT
15'	Molecular characterisation: Germline and somatic testing	Elena Castro, ES
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
15:25-15:55	Coffee break	
15:55-17:25 90'	SESSION 4 Castration-sensitive metastatic prostate cancer	Chairs: Karim Fizazi, FR Silke Gillessen, CH
20'	Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Silke Gillessen, CH
15'	Triplet and quadruplet options (mCSPC)	Karim Fizazi, FR
10'	Monitoring of mCSPC	Ken Herrmann, DE
15'	Oligo-metastatic disease: What treatment?	Thomas Zilli, CH
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
19:30	Networking Dinner	

Thursday, 19 December 2024

09:00-10:45 105'	SESSION 5 Non metastatic and metastatic castration-resistant disease	Chairs: Giulia Baciarello, IT Elena Castro, ES
20'	Non metastatic CRPC: Current treatment	Giulia Baciarello, IT
20'	Metastatic CRPC: Current treatment	Silke Gillessen, CH
20'	PSMA-based therapies	Ken Herrmann, DE
15'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
10:45-11:15	Coffee break	
11:15-12:20 65'	SESSION 6 Metastatic castration-resistant disease	Chairs: Karim Fizazi, FR Silke Gillessen, CH
15'	Treatment in frail patients with mCRPC	Elena Castro, ES
20'	Experimental treatments for mCRPC	Karim Fizazi, FR
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
12:20-12:30 10'	Conclusion and farewell	Karim Fizazi, FR Silke Gillessen, CH
12:30-13:30	Lunch	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion